H.C. Wainwright Raises Palvella Therapeutics Price Target to $270
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has increased its price target for Palvella Therapeutics to $270 per share. This adjustment reflects a change in the expected value of the company, which could influence investor sentiment and trading behavior. The updated target suggests a new valuation based on current market conditions, which may impact the stock's performance. The previous target was not specified.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18
Aurum PropTech Focuses on Profits and Scale at Earnings Call
Oct 18